News Archive
Cantargia shows in-vivo proof of concept in malignant melanoma »
12-02-09
More attention on Cantargia in the internationally recognized magazine "BioCentury" »
12-01-31
ProNoxis has secured SEK 4.0 million in a new round of financing »
12-01-25
New rights issue in LU Bio February 2012 »
12-01-18
LUIS - LU Bio collaboration generates two new companies »
11-08-30
New investment in ProNoxis »
11-06-17
Attention on XImmune in BioCentury »
11-04-13
Cantargia builds power »
11-02-21
Continued progress in XImmune »
11-02-07
LU Bio acknowledged in high profile publication SciBX »
11-01-22
LU Bio sales of holdings »
10-12-08
Report on LU Bio portfolio company ProNoxis published in BioCentury »
10-10-07
LU Bio has decided to close the portfolio company Auril »
10-09-30
Article on Cantargia published in SciBX regarding “Homing in on CML stem cells“ »
10-09-17
LU Bio and Bio-Medisinsk Innovasjon AS in Oslo starts new co-operation »
10-09-13
LU Bio portfolio company Cantargia in the newsroom »
10-08-31
LU Bio dispose Oncorel holdings »
10-04-14
LU Bio portfolio company XImmune in the newsroom »
10-03-25
Dermagen reports successful phase I/IIa clinical trial »
09-12-02
LU Bioscience increases position in ProNoxis »
09-11-12
Successful findings from our portfolio company Auril noticed »
09-09-07
New investment dealing with temperature reduction in patients »
09-06-23
LU Bio announces a continued investment in Cytoguide ApS »
09-06-02
New portfolio company ProNoxis established »
09-06-01
Open seminar at Biomedical Center, Lund University, on March 25 »
09-03-15

New investment in ProNoxis

Share
| Print |
Tell a colleague

Tell a colleague about this

Your name
Recipient E-mail

Share this page

LinkedIn
Windows Live
Facebook
Google Bookmarks
del.icio.us
digg
FriendFeed
MySpace

With operations proceeding as planned, ProNoxis AB has secured SEK 4,0 million in a new round of financing. Signaling confidence in ProNoxis development to date, lead investor LU Bioscience invested SEK 2,5 million and Karolinska Development SEK 1,5 million and now hold 29,7 % and 17,6 % of ProNoxis, respectively.

Click here to read the press release                                


+46 (0)46 286 48 20
info@lubio.se
Ideon, Alfa 5
SE 223 70 Lund, Sweden
Lund University Bioscience AB
Contact us